Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds

ABSTRACT

Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease,  Typanosoma cruzi  infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I 
     
       
         
         
             
             
         
       
     
     in which R 1 , R 2 , R 3 , R 4 , X, Y and n have the meanings given in the specification.

This application is a Continuation of U.S. patent application Ser. No.13/063,894, which is a 371 National Stage filing of PCT/US2009/057729filed Sep. 21, 2009, which claims priority to U.S. ProvisionalApplication Ser. No. 61/099,030 filed Sep. 22, 2008, each of which isincorporated herein in its entirety.

The present invention relates to novel compounds, to pharmaceuticalcompositions comprising the compounds, to a process for making thecompounds and to the use of the compounds in therapy. More particularly,it relates to certain substituted imidazo[1,2-b]pyridazine compoundswhich exhibit Trk family protein tyrosine kinase inhibition, and whichare useful in the treatment of pain, inflammation, cancer and certaininfectious diseases.

The current treatment regimes for pain conditions utilize severalclasses of compounds. The opioids (such as morphine) have severaldrawbacks including emetic, constipatory and negative respiratoryeffects, as well as the potential for addictions. Non-steroidalanti-inflammatory analgesics (NSAIDs, such as COX-1 or COX-2 types) alsohave drawbacks including insufficient efficacy in treating severe pain.In addition, COX-1 inhibitors can cause ulcers of the mucosa.Accordingly, there is a continuing need for new and more effectivetreatments for the relief of pain, especially chronic pain.

Trk's are the high affinity receptor tyrosine kinases activated by agroup of soluble growth factors called neurotrophins (NT). The Trkreceptor family has three members—TrkA, TrkB and TrkC. Among theneurotrophins are (i) nerve growth factor (NGF) which activates TrkA,(ii) brain-derived neurotrophic factor (BDNF) and NT-4/5 which activateTrkB and (iii) NT3 which activates TrkC. Trk's are widely expressed inneuronal tissue and are implicated in the maintenance, signaling andsurvival of neuronal cells (Patapoutian, A. et al., Current Opinion inNeurobiology, 2001, 11, 272-280).

Inhibitors of the Trk/neurotrophin pathway have been demonstrated to beeffective in numerous pre-clinical animal models of pain. For example,antagonistic TrkA/NGF pathway antibodies (for example, RN-624) have beenshown to be efficacious in inflammatory and neuropathic pain animalmodels and in human clinical trials (Woolf, C. J. et al. (1994)Neuroscience 62,327-331; Zahn, P. K. et al. (2004) J. Pain 5, 157-163;McMahon, S. B. et al., (1995) Nat. Med. 1, 774-780; Ma, Q. P. and Woolf,C. J. (1997) Neuroreport 8, 807-810; Shelton, D. L. et al. (2005) Pain116, 8-16; Delafoy, L. et al. (2003) Pain 105, 489-497; Lamb, K. et al.(2003) Neurogastroenterol. Motil. 15, 355-361; Jaggar, S. I. et al.(1999) Br. J. Anaesth. 83, 442-448). Additionally, recent literatureindicates after inflammation, BDNF levels and TrkB signaling isincreased in the dorsal root ganglion (Cho, L. et al. Brain Research1997, 749, 358) and several studies have show antibodies that decreasesignaling through the BDNF/TrkB pathway inhibit neuronalhypersensitization and the associated pain (Chang-Qi, L et al. MolecularPain 2008, 4:27)

In addition it was shown that tumor cells and tumor invading macrophagessecret NGF which directly stimulates TrkA located on peripheral painfibers. Using various tumor models in both mouse and rats it wasdemonstrated that neutralizing NGF with a monoclonal antibody inhibitscancer related pain to a degree similar or superior to the highesttolerated dose of morphine. Therefore, an inhibitor of TrkA can be usedin the treatment of pain, including pain associated with cancer.

Recent literature has also shown that overexpression, activation,amplification and/or mutation of Trks are associated with many cancersincluding neuroblastoma (Brodeur, G. M., Nat. Rev. Cancer 2003, 3,203-216), ovarian cancer (Davidson. B., ct al., Clin. Cancer Res. 2003,9, 2248-2259), breast cancer (Kruettgen et al, Brain Pathology 2006, 16:304-310), prostate cancer (Dionne et al, Clin. Cancer Res. 1998, 4(8):1887-1898), pancreatic cancer (Dang et al, Journal of Gastroenterologyand Hepatology 2006, 21(5): 850-858), multiple myeloma (Hu et al, CancerGenetics and Cytogenetics 2007, 178: 1-10), astrocytoma andmedulloblastoma (Kruettgen et al, Brain Pathology 2006, 16: 304-310)glioma (Hansen et al, Journal of Neurochemistry 2007, 103: 259-275),melanoma (Truzzi et al, Journal of Investigative Dermatology 2008,128(8): 2031-2040, thyroid carcinoma (Brzezianska et al,Neuroendocrinology Letters 2007, 28(3), 221-229.), lung adenocarcinoma(Perez-Pincra ct al, Molecular and Cellular Biochemistry 2007, 295(1&2),19-26), large cell neuroendocrine tumors (Marchetti et al, HumanMutation 2008, 29(5), 609-616), and colorectal cancer (Bardelli, A.,Science 2003, 300, 949). In preclinical models of cancer, non-selectivesmall molecule inhibitors of Trk A, B and C and Trk/Fc chimeras wereefficacious in both inhibiting tumor growth and stopping tumormetastasis (Nakagawara, A. (2001) Cancer Letters 169:107-114; Meyer, J.et al. (2007) Leukemia, 1-10; Pierottia, M. A. and Greco A., (2006)Cancer Letters 232:90-98; Eric Adriaenssens, E. et al. Cancer Res (2008)68:(2) 346-351) (Truzzi et al, Journal of Investigative Dermatology2008, 128(8): 2031-2040.

In addition, inhibition of the neurotrophin/Trk pathway has been shownto be effective in treatment of pre-clinical models of inflammatorydisease. For example inhibition of the neurotrophin/Trk pathway has beenimplicated preclinical models of inflammatory lung disease includingasthma (Freund-Michel, V; Frossard, N.; Pharmacology & Therapeutics(2008), 117(1), 52-76), interstitial cystitis (Hu Vivian Y; et. al. TheJournal of Urology (2005), 173(3), 1016-21), inflammatory bowel diseaseincluding ulcerative colitis and Crohn's disease (Di Mola, F. F, et.al., Gut (2000), 46(5), 670-678) and inflammatory skin diseases such asatopic dermatitis (Dou, Y.-C.; et. al. Archives of DermatologicalResearch (2006), 298(1), 31-37), eczema and psoriasis (Raychaudhuri, S.P.; et. al. Journal of Investigative Dermatology (2004), 122(3),812-819).

The neurotrophin/Trk pathway, particularly BDNF/TrkB, has also beenimplicated in the etiology neurodegenerative diseases including multiplesclerosis, Parkinson's disease and Alzheimer's disease (Sohrabji,Farida; Lewis, Danielle K. Frontiers in Neuroendocrinology (2006),27(4), 404-414). Modulation of the neutrophin/Trk pathway may haveutility in treatment of these and related diseases.

The TrkA receptor is also thought to be critical to the disease processin the infection of the parasitic infection of Typanosoma cruzi (Chagasdisease) in human hosts (de Melo-Jorge, M. et al. Cell Host & Microbe(2007), 1(4), 251-261). Thus, TrkA inhibition my have utility intreating Chagas disease and related protozoan infections.

Trk inhibitors may also find use in treating disease related to animbalance of the regulation of bone remodeling, such as osteoporosis,rheumatoid arthritis and bone metastases. Bone metastases are a frequentcomplication of cancer, occurring in up to 70 percent of patients withadvanced breast or prostate cancer(1) and in approximately 15 to 30percent of patients with carcinoma of the lung, colon, stomach, bladder,uterus, rectum, thyroid, or kidney. Osteolytic metastases can causesevere pain, pathologic fractures, life-threatening hypercalcemia,spinal cord compression, and other nerve-compression syndromes. Forthese reasons, bone metastasis is a serious and costly complication ofcancer. Therefore, agents that can induce apoptosis of proliferatingosteoblasts would be highly advantageous. Expression of TrkA and TrkCreceptors has been observed in the bone forming area in mouse models ofbone fracture (K. Asaumi, et al., Bone (2000) 26(6) 625-633). Inaddition, localization of NGF was observed in almost all bone formingcells (K. Asaumi, et al.). Recently, it was demonstrated that a pan-Trkinhibitor inhibits the tyrosine signaling activated by neurotrophinsbinding to all three of the Trk receptors in human hFOB osteoblasts (J.Pinski, et al., (2002) 62, 986-989). These data support the rationalefor the use of Trk inhibitors for the treatment of bone remodelingdiseases, such as bone metastases in cancer patients.

Several classes of small molecule inhibitors of Trk kinases said to beuseful for treating pain or cancer are known (Expert Opin. Ther. Patents(2009) 19(3)). International Patent Application Publications WO2006/115452 and WO 2006/087538 describe several classes of smallmolecules said to be inhibitors or Trk kinases which could be useful fortreating pain or cancer.

U.S. Patent Publication number 2007/025540 discloses certain substitutedimidazo[1,2b]pyridazines having a secondary amino group or aBOC-protected piperazinyl group at the 6-position. These compounds aredisclosed as being inhibitors of the protein kinase C (PKC).

International Publication No. WO 2008/052734 discloses(R)-4-(6-(2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)benzonitrile,that is, an imidazo[1,2b]pyridazine compound bearing an aryl-substitutedheterocyclic group at the 6-position and a benzonitrile group at the 3position. This compound does not fall within the general formulaedisclosed therein representing 3-aryl substitutedimidazo[1,2-b]pyridazines. This compound is purported to be suitable fortreating diseases mediated by the PI3K receptor, the JAK-2 receptor andthe Trk receptor.

International Publication No. WO 2007/013673 discloses1-phenyl-3-(6-(1-phenylethylamino)imidazo[1,2-b]pyridazin-3-yl)urea andN-(6-(4-hydroxycyclohexylamino) imidazo[1,2-b]pyridazin-3-yl)benzamide,that is, imidazo[1,2b]pyridazine compounds bearing an amino group at the6-position and an amide or urea moiety at the 3 position. Thesecompounds are said to be Lck inhibitors.

There is a continuing need for new and more effective treatments for therelief of pain, especially chronic pain. Because TrkA and other Trkkinases may serve as a mediator of NGF driven biological responses,inhibitors of TrkA and other Trk kinases may provide an effectivetreatment for chronic pain states.

It has now been found that certain imidazo[1,2b]pyridazine compoundsbearing an aryl or heteroaryl-substituted heterocyclic group at the6-position and a group having the formula NR¹C(═O)R² at the 3-position,wherein R¹ and R² are as defined herein, are inhibitors of Trk kinases,in particular inhibitors of TrkA and/or TrkB, which are useful fortreating disorders and diseases which can be treated by inhibiting Trk-Aand/or TrkB kinases, such as pain, including chronic and acute pain, orcancer. Certain compounds of the invention which are inhibitors of TrkAand/or TrkB may be useful in the treatment of multiple types of pain(including acute and chronic pain) including inflammatory pain,neuropathic pain, and pain associated with cancer, surgery and bonefracture. In addition, compounds of the invention may be useful fortreating cancer, inflammation, neurodegenerative diseases and certaininfectious diseases.

Accordingly, one embodiment of this invention provides a compound of thegeneral Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is H or (1-6C alkyl);

R² is NR^(b)R^(c), (1-4C)alkyl, (1-4C)fluoro alkyl, CF₃,(1-4C)hydroxyalkyl, -(1-4C alkyl)hetAr¹, -(1-4C alkyl)NH(1-4C alkyl),hetAr², hetCyc¹, hetCyc², phenyl which is optionally substituted withNHSO₂(1-4C alkyl), or (3-6C)cycloalkyl which is optionally substitutedwith (1-4C alkyl), CN, OH, CF₃, CO₂(1-4C alkyl) or CO₂H;

R^(b) is H or (1-6C alkyl);

R^(c) is H, (1-4C)alkyl, (1-4C)hydroxyalkyl, hetAr³, or phenyl, whereinsaid phenyl is optionally substituted with one or more substituentsindependently selected from halogen, CN, CF₃ and —O(1-4C alkyl),

or NR^(b)R^(c) forms a 4 membered heterocyclic ring having a ringnitrogen atom wherein said heterocyclic ring is optionally substitutedwith one or more substituents independently selected from halogen, OH,(1-4C alkyl), (1-4 C)alkoxy, —OC(═O)(1-4C alkyl), NH₂, —NHC(═O)O(1-4Calkyl), and (1-4C)hydroxyalkyl,

or NR^(b)R^(c) forms a 5-6 membered heterocyclic ring having a ringheteroatom which is nitrogen and optionally having a second ringheteroatom or group selected from N, O and SO₂, wherein the heterocyclicring is optionally substituted with one or more substituentsindependently selected from OH, halogen, CF₃, (1-4C)alkyl, CO₂(1-4Calkyl), CO₂H, NH₂, NHC(═O)O(1-4C alkyl) and oxo,

or NR^(b)R^(c) forms a 7-8 membered bridged heterocyclic ring having 1-2ring nitrogen atoms and optionally substituted with CO₂(1-4C alkyl);

hetAr¹ is a 5-membered heteroaryl ring having 1-3 ring nitrogen atoms;

hetAr² is 5-6 membered heteroaryl ring having at least one nitrogen ringatom and optionally having a second ring heteroatom independentlyselected from N and S, wherein said heteroaryl ring is optionallysubstituted with one or more substituents independently selected from(1-4C alkyl), halogen, -(1-4 C)alkoxy, and NH(1-4C alkyl);

hetCyc¹ is a carbon-linked 4-6 membered azacyclic ring optionallysubstituted with one or more substituents independently selected from(1-4C alkyl), CO₂H and CO₂(1-4C alkyl);

hetCyc² is a pyridinone or pyridazinone ring substituted with asubstituent selected from (1-4C)alkyl;

hetAr³ is a 5-6 membered heteroaryl ring having 1-2 ring heteroatomsindependently selected from N and O and optionally substituted with oneor more substituents independently selected from (1-4C)alkyl;

Y is a phenyl ring optionally substituted with one or more substituentsindependently selected from halogen, (1-4C)alkoxy, CF₃ and CHF₂, or a5-6 membered heteroaryl ring having a ring heteroatom selected from Nand S;

X is null, —CH₂—, CH₂CH₂—, —CH₂O—, or —CH₂NR^(d)—;

R^(d) is H or (1-4C alkyl);

R³ is H or (1-4C alkyl);

each R⁴ is independently selected from halogen, (1-4C)alkyl, OH, (1-4C)alkoxy, NH₂, NH(1-4C alkyl) and CH₂OH; and

n is 0, 1, 2, 3, 4, 5 or 6.

In certain embodiments of Formula I, R¹ is hydrogen.

In certain embodiments of Formula I, R¹ is (1-6C)alkyl. A particularexample is methyl.

In certain embodiments of Formula I, R² is a group having the formulaNR^(b)R^(c), such that the group at the 3 position of theimidazo[1,2b]pyridazine core of Formula I has the formula—NR¹C(═O)NR^(b)R^(c).

In certain embodiments, R^(b) is H. In certain embodiments, R^(b) is(1-6C alkyl), for example Me. In certain embodiments, R^(c) is H,(1-4C)alkyl, (1-4C)hydroxyalkyl, hetAr³, or phenyl, wherein said phenylis optionally substituted with one or more substituents independentlyselected from halogen, CN, CF₃ and —O(1-4C alkyl).

In certain embodiments, R² is NR^(b)R^(c), where R^(c) is hydrogen. Inparticular embodiments, the group represented by NR^(b)R^(c) is NH₂.

In certain embodiments, R² is NR^(b)R^(c), where R^(c) is (1-4C)alkyl.Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, andthe like. In particular embodiments, the group represented byNR^(b)R^(c) includes NHMe, NMe₂ and NH(t-butyl).

In certain embodiments, R² is NR^(b)R^(c), where Re is(1-4C)hydroxyalkyl. Examples include CH₂CH₂OH and CH₂CH₂CH₂OH. Inparticular embodiments, the group represented by NR^(b)R^(c) includesNMe(CH₂CH₂OH).

In certain embodiments, R² is NR^(b)R^(c), where R^(c) is hetAr³, andhetAr³ is an optionally substituted 5-6 membered heteroaryl ring having1-2 ring heteroatoms independently selected from N and O. An example ofhetAr³ includes an isoxazolyl ring. In certain embodiments, hetAr³ isunsubstituted. In other embodiments, hetAr³ is substituted with one ormore substituents independently selected from (1-4C)alkyl, for exampleone or more substituents independently selected from methyl and ethyl.Examples of hetAr³ include dimethylisoxazolyl. In particularembodiments, the group represented by NR^(b)R^(c) includes the grouphaving the structure:

In certain embodiments, R² is NR^(b)R^(c), where R^(c) is a phenyl groupoptionally substituted with one or more substituents independentlyselected from halogen, CN, CF₃ and O-(1-4C alkyl). Examples of R^(c)include phenyl, fluorophenyl, chlorophenyl, cyanophenyl, methoxyphenyl,trifluoromethylphenyl, dichlorophenyl, and trimethoxyphenyl. Moreparticular examples include 4-fluorophenyl, 3-chlorophenyl,4-chlorophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-methoxyphenyl,2-4-dichlorophenyl, 3-(trifluoromethyl)phenyl, 3,5-dichlorophenyl, and3,4,5-trimethoxyphenyl. In particular embodiments, the group representedby NR^(b)R^(c) includes groups having the structures:

In certain embodiments, R² is —NR^(b)R^(c), wherein:

(i) NR^(b)R^(c) forms a 4 membered heterocyclic ring having a ringnitrogen atom optionally substituted with one or more substituentsindependently selected from halogen, OH, (1-4C alkyl), (1-4 C)alkoxy,—OC(═O)(1-4C alkyl), NH₂, —NHC(═O)O(1-4C alkyl), and (1-4C)hydroxyalkyl,or

(ii) NR^(b)R^(c) forms a 5-6 membered heterocyclic ring having a ringheteroatom which is nitrogen and optionally having a second ringheteroatom or group selected from N, O and SO₂, wherein the heterocyclicring is optionally substituted with one or more substituentsindependently selected from OH, halogen, CF₃, (1-4C)alkyl, CO₂(1-4Calkyl), CO₂H, NH₂, NHC(═O)O(1-4C alkyl) and oxo, or

(iii) NR^(b)R^(c) forms a 7-8 membered bridged heterocyclic ring having1-2 ring nitrogen atoms and optionally substituted with CO₂(1-4C alkyl).

In certain embodiments, R² is —NR^(b)R^(c), wherein —NR^(b)R^(c) forms a4 membered heterocyclic ring having a ring nitrogen atom and which isoptionally substituted with one or more substituents independentlyselected from F, OH, (1-4C alkyl), —O(1-4C alkyl), —OC(═O)(1-4C alkyl),NH₂, —NHC(═O)O(1-4C alkyl), and (1-4C)hydroxyalkyl. Examples includeazetidinyl rings optionally substituted with one or more groupsindependently selected from OH, methyl, OMe, OC(═O)C(CH₃)₂, NH₂,—NHC(═O)OC(CH₃)₃ and CH₂OH. Particular examples of R² when representedby —NR^(b)R^(c), wherein —NR^(b)R^(c) forms a 4 membered heterocyclicring, include the structures:

In certain embodiments, R² is —NR^(b)R^(c), wherein —NR^(b)R^(c) forms a5-6 membered heterocyclic ring having a ring heteroatom which isnitrogen and optionally having a second ring heteroatom or groupselected from N, O and SO₂, wherein the heterocyclic ring is optionallysubstituted with one or more substituents independently selected fromOH, halogen, CF₃, (1-4C)alkyl, CO₂(1-4C alkyl), CO₂H, NH₂, NHC(═O)O(1-4Calkyl) and oxo. Examples include optionally substituted pyrrolidinyl,piperidinyl, piperazinyl, morpholinyl and piperidinesulfone rings.Examples of substituents on the 5-6 membered heterocyclic ring includeOH, F, NH₂, CO₂H, CO₂Et, NHCO₂C(CH₃)₃, CF₃, methyl, ethyl, isopropyl,CO₂C(CH₂)₃ and oxo. In one embodiment, the heterocyclic ring isoptionally substituted with one or two of said substituents. Particularexamples of R² when represented by —NR^(b)R^(c), wherein —NR^(b)R^(c)forms a 5-6 membered heterocyclic ring, include the structures:

In certain embodiments, R² is —NR^(b)R^(c), wherein NR^(b)R^(c) forms a7-8 membered bridged heterocyclic ring having 1-2 ring nitrogen atomsand optionally substituted with CO₂(1-4C alkyl). Examples of bridgedheterocyclic rings include diazabicyclooctane rings such as3,8-diazabicyclo[3.2.1]octane rings, which are optionally substitutedwith CO₂(1-4C alkyl), such as CO₂C(CH₃)₃. Particular examples of R² whenrepresented by —NR^(b)R^(c), wherein —NR^(b)R^(c) forms a 7-8 memberedbridged heterocyclic ring, include the structures:

In certain embodiments, R² is selected from (1-4C)alkyl,(1-4C)fluoroalkyl, CF₃, -(1-4C alkyl)hetAr¹, and -(1-4C alkyl)NH(1-4Calkyl). In certain embodiments, R² is selected from (1-4C)alkyl,(1-4C)fluoroalkyl, CF₃, -(1-4C)hydroxyalkyl, (1-4C alkyl)hetAr¹, and-(1-4C alkyl)NH(1-4C alkyl).

In certain embodiments, R² is (1-4C)alkyl. Particular examples includemethyl, isopropyl and tert-butyl.

In certain embodiments, R² is (1-4C)fluoroalkyl. A particular exampleincludes CF(CH₃)₂.

In certain embodiments, R² is CF₃.

In certain embodiments, R² is (1-4C)hydroxyalkyl. Particular examplesinclude C(CH₃)₂OH and C(CH₃)₂CH₂OH.

In certain embodiments, R² is (3-6C cycloalkyl) which is optionallysubstituted with (1-4C)alkyl, CN, OH, CF₃, CO₂(1-4C alkyl) or CO₂H. Incertain embodiments, R² is an optionally substituted cyclopropyl ring.Particular examples of R² include the structures:

In certain embodiments, R² is -(1-4C alkyl)hetAr¹, where hetAr¹ is a5-membered heteroaryl ring having 1-3 ring nitrogen atoms. An example ofhetAr¹ is a triazolyl ring, such as 1,2,4-triazolyl. Examples of the(1-4C)alkyl portion include methylene, ethylene, dimethylmethylene, andthe like. A particular value for R² when represented by -(1-4Calkyl)hetAr¹ is the structure:

In certain embodiments, R² is -(1-4C alkyl)NH(1-4C alkyl). Examplesinclude groups having the formula (1-4C alkyl)NHCH₃. A particular valueinclude C(CH₃)₂NHCH₃.

In certain embodiments, R² is selected from hetAr², hetCyc¹, hetCyc² andhetAr³. In certain embodiments, R² is selected from hetAr², hetCyc¹, andhetCyc².

In certain embodiments, R² is hetAr². Examples of hetAr² includepyridyl, pyrimidyl, pyrazinyl, pyrazolyl, imidazolyl and thiazolyl ringsoptionally substituted with one or more substituents independentlyselected from (1-4C alkyl), halogen, —O(1-4C alkyl), and NH(1-4C alkyl).Examples of substituents for hetAr² include methyl, ethyl, chloro, OMe,and NHCH(CH₃)₂. Particular values of R² include the structures:

In certain embodiments, R² is hetCyc¹. Examples of hetCyc¹ includecarbon-linked azetidinyl, pyrrolidinyl and piperidinyl rings optionallysubstituted with one or more substituents independently selected from(1-4C alkyl), CO₂H and CO₂(1-4C alkyl). Examples of substituents includemethyl, ethyl, propyl, CO₂H, CO₂Me, CO₂Et, and CO₂C(CH₃)₃. In oneembodiment, hetCyc¹ is optionally substituted with one or two of saidsubstituents. Particular values for R² represented by hetCyc¹ includethe structures:

In certain embodiments, R² is hetCyc². Examples include pyridinone orpyridazinone ring substituted with a substituent selected from(1-4C)alkyl such as a methyl or ethyl group. Particular values of R²when represented by hetCyc² include the structures:

In certain embodiments, R² is phenyl which is optionally substitutedwith an NHSO₂(1-4C alkyl) group such a methanesulfonamido or anethanesulfonamido group. Particular values for R² include thestructures:

Referring now to the substituents on the ring at the 6-position ofFormula I, in one embodiment Y is phenyl optionally substituted with oneor more substituents independently selected from halogen, (1-4C)alkoxy,CF₃ and CHF₂. In one embodiment, Y is phenyl optionally substituted withone or more substituents independently selected from F, Cl, OMe, CF₃ andCHF₂. In certain embodiments, Y is phenyl optionally substituted withone or two of said substituents. Particular values for Y include phenyl,3-fluorophenyl, 2,5-difluorophenyl, 2-chloro-5-fluorophenyl,2-methoxyphenyl, 2-methoxy-5-fluorophenyl,2-trifluoromethyl-5-fluorophenyl, 2-difluoromethyl-5-fluorophenyl and3-chloro-5-fluorophenyl.

In one embodiment, Y is a 5-6 membered heteroaryl ring having a ringheteroatom selected from N and S. Examples include pyridyl and thienylgroups. Particular values for Y include 2-pyridyl, 3-pyridyl and2-thienyl.

In one embodiment, the Y group has the absolute configuration shown inFigure Ia:

With reference to the R³ substituent, in one embodiment R³ is H. In oneembodiment, R³ is (1-4C)alkyl, for example, methyl, ethyl, propyl,isopropyl, or butyl. Particular values for R³ include hydrogen andmethyl.

With reference to the R⁴ substituent, in one embodiment R⁴ is halogen.Particular examples are fluoro and chloro.

In one embodiment, R⁴ is (1-4C)alkyl, such as methyl, ethyl, propyl,isopropyl, or butyl. A particular example is methyl.

In one embodiment, R⁴ is OH.

In one embodiment, R⁴ is (1-4 C)alkoxy, for example OMe and OEt.

In one embodiment, R⁴ is NH₂.

In one embodiment, R⁴ is NH(1-4C alkyl), for example NHMe, NHEt, NHPr,NHiPr and NHBu. A particular example is NHMe.

In one embodiment, R⁴ is CH₂OH.

In one embodiment, each R⁴ is independently selected from F, Cl, OH,OMe, NH₂, Me, CH₂OH, and NHMe.

In one embodiment, n is 0, 1, 2, 3 or 4. In one embodiment, n is 0, 1, 2or 3. In one embodiment, n is 0, 1 or 2.

With continued reference to the ring at the 6-position of Formula I, incertain embodiments, X is null, —CH₂— or CH₂CH₂—.

In one embodiment X is null, such that the heterocyclic ring at the6-position of Formula I has the structure:

where R³, R⁴, Y and n are as defined herein. In one embodiment, Y isphenyl optionally substituted with one or two F. In one embodiment, Y isa 5-6 membered heteroaryl ring. In one embodiment, R³ is hydrogen. Inanother embodiment, R³ is methyl. A particular example of the ring atthe 6-position of Formula I when X is null includes the structures:

In one embodiment, X is CH₂, such that the heterocyclic ring at the6-position of Formula I has the structure:

where R³, R⁴, Y and n are as defined herein. In one embodiment Y isphenyl substituted with one or two fluoro atoms. In one embodiment, R³is hydrogen. In another embodiment, R³ is methyl. In one embodiment,each R⁴ is independently selected from F, Cl, Me, OH, OMe, NH₂, NHMe,CH₂OH, CHF₂ and CF₃. In one embodiment, n is 0, 1 or 2. Particularexamples of the ring at the 6-position of Formula I when X is CH₂include the structures:

In one embodiment, X is CH₂, such that the heterocyclic ring at the6-position of Formula I has the structure:

where R³, R⁴, Y and n are as defined herein. In one embodiment, Y is a5-6 membered heteroaryl ring having a ring heteroatom selected from Nand S. Examples of 5-6 membered heteroaryl rings include pyridyl andthienyl. In one embodiment, R³ is hydrogen. In another embodiment, R³ ismethyl. In one embodiment, each R⁴ is independently selected from F, Cl,Me, OH, OMe, NH₂, NHMe and CH₂OH. In one embodiment, n is 0, 1 or 2. Inone embodiment, n is 0. Particular examples of the ring at the6-position of Formula I when X is CH₂ include the structures:

In one embodiment, X is CH₂CH₂, such that the heterocyclic ring at the6-position of Formula I has the structure:

where R³, R⁴, Y and n are as defined herein. In one embodiment, Y isphenyl optionally substituted with one or two fluoro atoms. In oneembodiment, Y is a pyridyl ring. In one embodiment, R³ is hydrogen. Inanother embodiment, R³ is methyl. In one embodiment, n is 0, 1 or 2. Inone embodiment, n is 0. Particular examples of the ring at the6-position of Formula I when X is CH₂CH₂ include the structures:

In one embodiment, X is —CH₂O—, such that the heterocyclic ring at the6-position of Formula I has the structure:

where R³, R⁴, Y and n are as defined herein. In one embodiment, Y isphenyl optionally substituted with one or more substituentsindependently selected from F and (1-4C)alkoxy, for example one or twosubstituents independently selected from F and OMe. In one embodiment, Yis fluorophenyl, difluorophenyl or methoxyphenyl. In one embodiment, Yis pyridyl. In one embodiment, R³ is hydrogen. In another embodiment, R³is methyl. In one embodiment, n is 0, 1 or 2. Particular examples of thering at the 6-position of Formula I when X is —CH₂O— include thestructures:

In one embodiment, X is —CH₂NR^(d)—, such that the heterocyclic ring atthe 6-position of Formula I has the structure:

where R³, R⁴, Y, R^(d) and n are as defined herein. In one embodiment,R^(d) is H. In one embodiment, R^(d) is (1-4C alkyl), for examplemethyl, ethyl, propyl, isopropyl, or butyl. A particular example ismethyl. In one embodiment, Y is phenyl optionally substituted with oneor two F. In one embodiment, n is 0. Particular examples of the ring atthe 6-position of Formula I when X is —CH₂NR^(d)— include thestructures:

Compounds of Formula I include compound of Formula Ib, wherein:

R¹ is H or (1-6C alkyl);

R² is NR^(b)R^(c);

NR^(b)R^(c) forms a 4 membered heterocyclic ring having a ring nitrogenatom, wherein said heterocyclic ring is optionally substituted with oneor more substituents independently selected from halogen, OH, (1-4Calkyl), (1-4 C)alkoxy, —OC(═O)(1-4C alkyl), NH₂, —NH C(═O)O (1-4C alkyl)and (1-4C)hydroxyalkyl,

or NR^(b)R^(c) forms a 5-6 membered heterocyclic ring having a ringheteroatom which is nitrogen and optionally having a second ringheteroatom or group selected from N, O and SO₂, wherein the heterocyclicring is optionally substituted with one or more substituentsindependently selected from OH, halogen, CF₃, (1-4C)alkyl, CO₂(1-4Calkyl), CO₂H, NH₂, NHC(═O)O(1-4C alkyl) and oxo;

Y is phenyl optionally substituted with one or more substituentsindependently selected from halogen, (1-4C)alkoxy, CF₃ and CHF₂;

X is null, —CH₂—, or CH₂CH₂—;

R³ is H or (1-4C alkyl);

each R⁴ is independently selected from halogen, (1-4C)alkyl, OH, (1-4C)alkoxy, NH₂, NH(1-4C alkyl) and CH₂OH; and

n is 0, 1, or 2.

In one embodiment of Formula Ib, Y is phenyl optionally substituted withone or more halogen atoms. In one embodiment of Formula Ib, Y is phenyloptionally substituted with one or two fluorine atoms.

In one embodiment of Formula Ib, (i) NR^(b)R^(c) forms a 4 memberedheterocyclic ring having a ring nitrogen atom, wherein said ring isoptionally substituted with one or more substituents independentlyselected from halogen, OH, (1-4C alkyl), (1-4 C)alkoxy, —OC(═O)(1-4Calkyl), NH₂, —NHC(═O)O(1-4C alkyl) and (1-4C)hydroxyalkyl, or (ii)NR^(b)R^(c) forms a 5-6 membered heterocyclic ring having a ringheteroatom which is nitrogen and optionally having a second ringheteroatom or group selected from N, O and SO₂, wherein the heterocyclicring is optionally substituted with one or more substituentsindependently selected from OH, halogen, CF₃, (1-4C)alkyl, CO₂(1-4Calkyl), CO₂H, NH₂, NHC(═O)O(1-4C alkyl) and oxo.

In one embodiment of Formula Ib, n is zero or one.

In one embodiment of Formula Ib, R³ is hydrogen.

Compounds of Formula Ib include compounds of Formula Ic wherein:

R¹ is H or (1-6C alkyl);

R² is NR^(b)R^(c);

NR^(b)R^(c) forms a 4 membered heterocyclic ring having a ring nitrogenatom, wherein said heterocyclic ring is optionally substituted with oneor more substituents independently selected from halogen, OH, (1-4Calkyl), (1-4 C)alkoxy, —OC(═O)(1-4C alkyl), NH₂, —NHC(═O)O(1-4C alkyl)and (1-4C)hydroxyalkyl;

Y is phenyl optionally substituted with one or more substituentsindependently selected from halogen, (1-4C)alkoxy, CF₃ and CHF₂;

X is —CH₂—;

R³ is H or (1-4C alkyl);

each R⁴ is independently selected from halogen, (1-4C)alkyl, OH, (1-4C)alkoxy, NH₂, NH(1-4C alkyl) and CH₂OH; and

n is 0, 1, or 2.

In one embodiment of Formula Ic, the heterocyclic ring formed byNR^(b)R^(c) is optionally substituted with one or two substituentsindependently selected from F, OH, methyl, OMe, OC(═O)C(CH₃)₂, NH₂,—NHC(═O)OC(CH₃)₃ and CH₂OH.

In one embodiment of Formula Ic, Y is phenyl optionally substituted withone or more halogen atoms. In one embodiment of Formula Ic, Y is phenyloptionally substituted with one or two fluorine atoms.

Compounds of Formula Ib also include compounds of Formula Id wherein:

R¹ is H or (1-6C alkyl);

R² is NR^(b)R^(c);

NR^(b)R^(c) forms a 5-6 membered heterocyclic ring having a ringheteroatom which is nitrogen and optionally having a second ringheteroatom or group selected from N, O and SO₂, wherein the heterocyclicring is optionally substituted with one or more substituentsindependently selected from OH, halogen, CF₃, (1-4C)alkyl, CO₂(1-4Calkyl), CO₂H, NH₂, NHC(═O)O(1-4C alkyl) and oxo;

Y is phenyl optionally substituted with one or more substituentsindependently selected from halogen, (1-4C)alkoxy, CF₃ and CHF₂;

X is —CH₂—;

R³ is H or (1-4C alkyl);

each R⁴ is independently selected from halogen, (1-4C)alkyl, OH, (1-4C)alkoxy, NH₂, NH(1-4C alkyl) and CH₂OH; and

n is 0, 1, or 2.

In one embodiment of Formula Id, the heterocyclic ring formed byNR^(b)R^(c) is optionally substituted with one or two substituentsindependently selected from OH, F, NH₂, CO₂H, CO₂Et, NHCO₂C(CH₃)₃, CF₃,methyl, ethyl, isopropyl, CO₂C(CH₃)₃ and oxo.

In one embodiment of Formula Id, the heterocyclic ring formed byNR^(b)R^(c) is a 5-6 membered azacyclic ring.

In one embodiment of Formula Id, Y is phenyl optionally substituted withone or more halogen atoms. In one embodiment of Formula Id, Y is phenyloptionally substituted with one or two fluorine atoms.

In one embodiment of Formula Ic or Id, n is zero or one.

In one embodiment of Formula Ic or Id, R³ is hydrogen.

In one embodiment of Formula Ic or Id, R¹ is hydrogen.

It will be appreciated that certain compounds according to the inventionmay contain one or more centers of asymmetry and may therefore beprepared and isolated in a mixture of isomers such as a racemic mixture,or in an enantiomerically pure form. It is intended that allstereoisomeric forms of the compounds of the invention, including butnot limited to, diastereomers, enantiomers and atropisomers, as well asmixtures thereof such as racemic mixtures, form part of the presentinvention.

In the structures shown herein, where the stereochemistry of anyparticular chiral atom is not specified, then all stereoisomers arecontemplated and included as the compounds of the invention. Wherestereochemistry is specified by a solid wedge or dashed linerepresenting a particular configuration, then that stereoisomer is sospecified and defined.

It will also be appreciated that certain compounds of Formula I may beused as intermediates for further compounds of Formula I.

The compounds of Formula I include pharmaceutically acceptable saltsthereof. In addition, the compounds of Formula I also include othersalts of such compounds which are not necessarily pharmaceuticallyacceptable salts, and which may be useful as intermediates for preparingand/or purifying compounds of Formula I and/or for separatingenantiomers of compounds of Formula I. Particular examples includehydrochloride and trifluoroacetate salts of compounds of Formula I.

It will further be appreciated that the compounds of Formula I or theirsalts may be isolated in the form of solvates, and accordingly that anysuch solvate is included within the scope of the present invention.

The term “(1-4C) alkyl” as used herein refers to saturated linear orbranched-chain monovalent hydrocarbon radicals of one to four carbonatoms, respectively. Examples include, but are not limited to, methyl,ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, and2-methyl-2-propyl.

The term “(1-4C) alkoxy” as used herein refers to saturated linear orbranched-chain monovalent radicals of one to four carbon atoms,respectively, wherein the radical is on the oxygen atom.

The term “(1-4C)hydroxyalkyl” as used herein refers to saturated linearor branched-chain monovalent hydrocarbon radicals of one to four carbonatoms, respectively, wherein one of the hydrogen atoms is replaced withan OH group.

The term “halogen” includes fluoro, chloro, bromo and iodo.

According to another aspect, the present invention provides a processfor the preparation of a compound of Formula I or a pharmaceuticallyacceptable salt thereof as defined herein which comprises:

-   -   (a) for a compound of Formula I wherein R² is NR^(b)R^(c),        reacting a corresponding compound of formula II

-   -   with a compound having the formula HNR^(b)R^(c) in the presence        of a coupling reagent; or    -   (b) for a compound of Formula I wherein R² is NR^(b)R^(c) and        R^(b) is H, reacting a corresponding compound of formula II with        a compound having the formula O═C═N—R^(c); or    -   (c) for a compound of Formula I wherein R² is hetAr² or a phenyl        ring which is optionally substituted with NHSO₂(1-4C alkyl),        reacting a corresponding compound of Formula II with a        corresponding compound having the formula HOC(═O)R² in the        presence of a coupling reagent and a base; or    -   (d) for a compound of Formula I wherein R² is (1-4C)alkyl,        (1-4C)fluoroalkyl, CF₃, (1-4C)hydroxyalkyl, or (3-6C)cycloalkyl        which is optionally substituted with (1-4C alkyl), CN, OH, CF₃,        CO₂(1-4C alkyl) or CO₂H, reacting a corresponding compound of        Formula II with a corresponding compound having the formula        (R²CO)₂O in the presence of a base; and    -   (e) removing or adding any protecting groups if desired, and        forming a salt if desired.

Referring to method (a), examples of coupling reagents include any knowncoupling reagent, for examples peptide coupling reagents such as CDI(carbonyl diimidazole), DCC (N,N′-dicyclohexylcarbodiimide), and EDCI(1-(3-dimethylaminopropyl)-3-ethylcarbodiimide). The reaction isoptionally performed in the presence of an amine base, such as DIEA(diisopropylethylamine). Suitable solvents include dichloromethane,dichloroethane, THF, and DMF. The reaction is conveniently performed atambient temperature.

Compounds of formula II

can be prepared by reducing a corresponding compound of formula III

under standard reducing conditions, for example reacting a compound offormula II with zinc dust under acidic conditions, such as in thepresence of an acid such as NH₄Cl.

Compounds of Formula III can be prepared by coupling a correspondingcompound having the formula IV

where Z is a leaving atom or group such as a halogen (for example Cl),with a corresponding compound having the formula V

where R³, R⁴, n, X and Y are as defined herein, in a suitable solventsuch as an alcohol (for example n-butanol or isopropanol), at elevatedtemperatures, for example at temperatures between 100 and 180° C., forexample at a temperature of about 140° C.

Compounds of the formula IV can be prepared from a correspondingcompound of Formula V

using standard nitrating conditions known in the art, for example byreacting a corresponding compound of Formula V with nitric acid in thepresence of an activating agent such as TFA or concentrated sulfuricacid. Compounds of Formula V are commercially available or can beprepared by standard methods known in the art.

Compounds of Formula II and III are also believed to be novel andprovide a further embodiment of this invention.

Referring to method (b), suitable solvents include dichloromethane,dichloroethane, THF, and DMF. The reaction is conveniently performed atambient temperature.

Referring to method (c), suitable coupling reagents include HATU, HBTUand other coupling reagents well known to persons skilled in the art.Suitable bases include amine bases such as diisopropylethylamine (DIEA)and triethylamine. Suitable solvents include DMF and CH₃CN. The reactionis conveniently performed at temperatures between 0° C. and ambienttemperature.

Referring to method (d), suitable bases include amine bases such aspyridine or triethylamine. Suitable solvents include dichloromethane anddichloroethane. The reaction is conveniently performed at temperaturesbetween 0° C. and ambient temperature.

Referring to method (e), suitable bases include amine bases (for exampleDIEA or triethylamine) and alkali metal carbonate bases (for example,potassium carbonate or sodium carbonate). In certain embodiments,compounds of formula II are treated with an amine base, and subsequentlythe chloroformate compound is added followed by the addition of thealkali metal carbonate base. Suitable solvents include DCM, DCE and THF.The reaction is conveniently performed at ambient temperature.

The ability of compounds to act as Trk-A inhibitors may be demonstratedby the assays described in Examples A and B. The ability of compounds toact as Trk-A inhibitors may be demonstrated by the assay described inExample B.

Compounds of Formula I are useful for treating chronic and acute pain,including pain associated with cancer. Certain compounds which areinhibitors of TrkA and/or TrkB may be useful in the treatment ofmultiple types of pain including inflammatory pain, neuropathic pain,and pain associated with cancer, surgery, and bone fracture.

Compounds of Formula I are also useful for treating cancers includingneuroblastoma, ovarian, pancreatic and colorectal cancer.

Compounds of Formula I are also useful for treating inflammation andcertain infectious diseases.

In addition, compounds of Formula I may also be used to treatinterstitial cystitis (IC), painful bladder syndrome (PBS), urinaryincontinence, asthma, anorexia, atopic dermatitis, and psoriasis.

Compounds of Formula I may also be used to treat demyelination anddysmyelination by promoting myelination, neuronal survival, andoligodendrocyte differentiation via blocking Sp35-TrkA interaction.

Compounds of Formula I may be of therapeutic value for the useful in thetreatment of bone-related diseases (such as those involving boneresorption). Examples of bone-related diseases include metastatic bonedisease, treatment-induced bone loss, osteoporosis, rheumatoidarthritis, ankylosing spondylitis, Paget's disease, and periodontaldisease. The osteoporosis may be attributed to (1) menopause in women,(2) aging in men or women, (3) suboptimal bone growth during childhoodand adolescence that resulted in failure to reach peak bone mass, and/or(4) bone loss secondary to other disease conditions, eating disorders,medications and/or medical treatments.

Other osteolytic diseases that can be treated according to the presentinvention are more localized. A particular example is metastatictumor-induced osteolysis. In this condition, bone cancers or bonemetastases induce localized osteolysis that causes pain, bone weaknessand fractures. Such localized osteolysis also permits tumors to growlarger by creating more space for them in the bone and releasing growthfactors from the bone matrix. Cancers presently known to causetumor-induced osteolysis include hematological malignancies (e.g.,myeloma and lymphoma) and solid tumors (e.g., breast, prostate, lung,renal and thyroid), all of which the present invention contemplatestreating.

As used herein, the term treatment includes prophylaxis as well astreatment of an existing condition.

Accordingly, another aspect of this invention provides a method oftreating diseases or medical conditions in a mammal, wherein saiddisease or condition is treatable with an inhibitor or Trk-A and/orTrk-B, comprising administering to said mammal one or more compounds ofFormula I or a pharmaceutically acceptable salt thereof in an amounteffective to treat or prevent said disorder. In a particular embodiment,the invention provides a method of treating pain, cancer, inflammation,neurodegenerative disease or Typanosoma cruzi infection in a mammal,which comprises administering to said mammal a therapeutically effectiveamount of a compound of Formula I or a pharmaceutically acceptable saltthereof. In another embodiment, the invention provides a method oftreating osteolytic disease in a mammal, which comprises administeringto said mammal a therapeutically effective amount of a compound ofFormula I or a pharmaceutically acceptable salt thereof.

The compounds of the present invention can be used in combination withone or more additional drugs that work by the same or a differentmechanism of action. Examples include anti-inflammatory compounds,steroids (e.g., dexamethasone, cortisone and fluticasone), analgesicssuch as NSAIDs (e.g., aspirin, ibuprofen, indomethacin, and ketoprofen),and opioids (such as morphine), and chemotherapeutic agents.

The phrase “effective amount” means an amount of compound that, whenadministered to a mammal in need of such treatment, is sufficient to (i)treat or prevent a particular disease, condition, or disorder which canbe treated with an inhibitor or Trk-A and/or Trk-B, (ii) attenuate,ameliorate, or eliminate one or more symptoms of the particular disease,condition, or disorder, or (iii) prevent or delay the onset of one ormore symptoms of the particular disease, condition, or disorderdescribed herein.

The amount of a compound of Formula I that will correspond to such anamount will vary depending upon factors such as the particular compound,disease condition and its severity, the identity (e.g., weight) of themammal in need of treatment, but can nevertheless be routinelydetermined by one skilled in the art.

As used herein, the term “mammal” refers to a warm-blooded animal thathas or is at risk of developing a disease described herein and includes,but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters,and primates, including humans.

Compounds of the invention may be administered by any convenient route,e.g. into the gastrointestinal tract (e.g. rectally or orally), thenose, lungs, musculature or vasculature, or transdermally or dermally.Compounds may be administered in any convenient administrative form,e.g. tablets, powders, capsules, solutions, dispersions, suspensions,syrups, sprays, suppositories, gels, emulsions, patches etc. Suchcompositions may contain components conventional in pharmaceuticalpreparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulkingagents, and further active agents. If parenteral administration isdesired, the compositions will be sterile and in a solution orsuspension form suitable for injection or infusion. Such compositionsform a further aspect of the invention.

According to another aspect, the present invention provides apharmaceutical composition, which comprises a compound of Formula I or apharmaceutically acceptable salt thereof, as defined hereinabove. In oneembodiment, the pharmaceutical composition includes the compound ofFormula I together with a pharmaceutically acceptable diluent orcarrier.

According to another aspect, the present invention provides a compoundof Formula I or a pharmaceutically acceptable salt thereof, for use intherapy, such as the treatment of a condition treatable with aninhibitor or Trk-A and/or Trk-B, such as one or more conditionsdescribed herein.

According to a further aspect, the present invention provides the use ofa compound of Formula I or a pharmaceutically acceptable salt thereof,in the treatment of a condition that can be treated with an inhibitor orTrk-A and/or Trk-B, such as a condition as defined hereinabove. In oneembodiment, the invention provides a compound of Formula I, or apharmaceutically acceptable salt thereof, for use in the treatment ofpain, cancer, inflammation, neurodegenerative disease or Typanosomacruzi infection.

In one embodiment, a compound of the invention is selected from any oneof:

-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-phenylurea;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)morpholine-4-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)acetamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-(methylsulfonamido)benzamide;-   (R)-1-(3-cyanophenyl)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea;-   (R)-1-(4-cyanophenyl)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea;-   (R)-1-(2,4-dichlorophenyl)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea;-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(3-(trifluoromethyl)phenyl)urea;-   (R)-1-(3,5-dichlorophenyl)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea;-   (S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;-   (R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;-   (R)-tert-butyl    1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidin-4-ylcarbamate;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxyazetidine-1-carboxamide;-   (R)-tert-butyl    1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)azetidin-3-ylcarbamate;-   (R)-tert-butyl    4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperazine-1-carboxylate;-   (R)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1,1-dimethylurea;-   tert-Butyl    1-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidin-3-ylcarbamate;-   (R)-4-amino-N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide;-   (R)-3-amino-N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)azetidine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperazine-1-carboxamide;-   3-Amino-N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide;-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(4-fluorophenyl)urea;-   tert-Butyl    3-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate;-   N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-hydroxypiperidine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide;-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea;-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-methylurea;-   (R)-1-tert-butyl-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea;-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(4-methoxyphenyl)urea;-   (R)-ethyl    1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidine-4-carboxylate;-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(3,4,5-trimethoxyphenyl)urea;-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(3,5-dimethylisoxazol-4-yl)urea;    (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidine-4-carboxylic    acid;-   N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,5-dimethylpiperazine-1-carboxamide;-   (R)-tert-butyl    4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-methylpiperazine-1-carboxylate;-   (S)-tert-butyl    4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-methylpiperazine-1-carboxylate;-   (R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-methylpiperazine-1-carboxamide;-   (S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-methylpiperazine-1-carboxamide;-   (3R,4R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,4-dihydroxypyrrolidine-1-carboxamide;-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidin-4-sulfone;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-oxopiperazine-1-carboxamide;-   N-(6-(2-(3-fluorophenyl)piperidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxyazetidine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-difluoropyrrolidine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-difluoroazetidine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)azetidine-1-carboxamide;-   (R)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-(2-hydroxyethyl)-1-methylurea;-   (R)-tert-butyl    4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2,2-dimethylpiperazine-1-carboxylate;-   (S)-tert-butyl    4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-isopropylpiperazine-1-carboxylate;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-dimethylpiperazine-1-carboxamide;-   (S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-isopropylpiperazine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-methoxyazetidine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxy-3-methylazetidine-1-carboxamide;-   (R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)azetidin-3-yl    isobutyrate;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-methylpiperazine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-hydroxy-4-(trifluoromethyl)piperidine-1-carboxamide;-   (R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-2,2,2-trifluoroacetamide;

and salts thereof. Particular examples of salts include hydrochlorideand trifluoroacetate salts.

EXAMPLES

The following examples illustrate the invention. In the examplesdescribed below, unless otherwise indicated all temperatures are setforth in degrees Celsius. Reagents were purchased from commercialsuppliers such as Aldrich Chemical Company, Lancaster, TCI or Maybridge,and were used without further purification unless otherwise indicated.Tetrahydrofuran (THF), dichloromethane (DCM, methylene chloride),toluene, and dioxane were purchased from Aldrich in Sure seal bottlesand used as received.

The reactions set forth below were done generally under a positivepressure of nitrogen or argon or with a drying tube (unless otherwisestated) in anhydrous solvents, and the reaction flasks were typicallyfitted with rubber septa for the introduction of substrates and reagentsvia syringe. Glassware was oven dried and/or heat dried.

Column chromatography was done on a Biotage system (Manufacturer: DyaxCorporation) having a silica gel column or on a silica SepPak cartridge(Waters).

Abbreviations used in the Examples have the following meanings:

CDI: carbonyl diimidazole

HATU: 2(1H-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uraniumhexafluoro-phophate methanaminium

DIEA: diisopropylethylamine

DMF: dimethylformamide

MTBE: methyl t-butyl ether

TFA: trifluoroacetic acid

ACN: acetonitrile

IPA: isopropyl alcohol

Example A TrkA ELISA Assay

An enzyme-linked immunosorbant assay (ELISA) was used to assess TrkAkinase activity in the presence of inhibitors. Immulon 4HBX 384-wellmicrotiter plates (Thermo part #8755) were coated with a 0.025 mg/mLsolution of poly (Glu, Ala, Tyr; 6:3:1; Sigma P3899). Variousconcentrations of test compound, 2.5 nM TrkA (Invitrogen Corp.,histidine-tagged recombinant human TrkA, cytoplasmic domain), and 500 μMATP were incubated for 25 minutes at ambient temperature in the coatedplates while shaking. The assay buffer consisted of 25 mM MOPS pH 7.5,0.005% (v/v) Triton X-100 and 5 mM MgCl₂. The reaction mixture wasremoved from the plate by washing with PBS containing 0.1% (v/v) Tween20. The phosphorylated reaction product was detected using 0.2 μg/mL ofa phosphotyrosine specific monoclonal antibody (clone PY20) conjugatedto horseradish peroxidase in conjunction with the TMB PeroxidaseSubstrate System (KPL). After the addition of 1M phosphoric acid, thechromogenic substrate color intensity was quantitated via absorbance at450 nm. IC₅₀ values were calculated using either a 4 or 5-parameterlogistic curve fit.

In this assay, compounds of the invention had an average IC₅₀ below 1000nM. Certain compounds had an average IC₅₀ below 100 nM.

Table 1 provides IC₅₀ values for compounds of the invention when testedin this assay.

TABLE 1 TrkA Elisa Enzyme Example # IC₅₀ (nM) 1 8.3 2 23.7 3 5.4 4 2.1 574.2 6 10.7 7 39.4 8 507.8 9 716.7 10 3.8 11 15.5 12 17.2 13 9.4 14 23.215 33.6 16 18 17 13.8 18 52.9 19 126.3 20 94.7 21 42 22 10 23 75.5 24107.1 25 13.8 26 7.1 27 77.1 28 65.7 29 9.8 30 5.5 31 20.1 32 175.6 33901 34 64.4 35 49.6 36 13 37 40.6 38 47.9 39 29.9 40 2.2 41 884.4 4226.2 43 215.6 44 22.7 45 92 46 17.9 47 10.3 48 8.3 49 857 50 60.6 5127.7 52 14 53 16.4 54 8.9 55 19.4 56 10.2 57 2.3 58 53.2 59 16.5 60 22

Example B TrkA and TrkB Omnia Assay

Trk enzymatic selectivity was assessed using Omnia™ Kinase Assayreagents from Invitrogen Corp. Enzyme (either TrkA or TrkB fromInvitrogen Corp.) and test compound (various concentrations) wereincubated for 10 minutes at ambient temperature in a 384-well whitepolypropylene plate (Nunc catalog #267462). Omnia Tyr Peptide #4 (forTrkA) or #5 (for TrkB), as well as ATP, were then added to the plate.Final concentrations were as follows: 20 nM enzyme, 500 μM of ATP forTrkA assay or 1 mM ATP for TrkB assay, 10 μM peptide substrate. Theassay buffer consisted of 25 mM MOPS pH 7.5, 0.005% (v/v) Triton X-100and 5 mM MgCl₂. The production of phosphorylated peptide was monitoredcontinuously for 70 minutes using a Molecular Devices FlexStation II³⁸⁴microplate reader (excitation=360 nm; emission=485 nm). Initial rateswere calculated from the progress curves. IC₅₀ values were thencalculated from these rates using either a 4 or 5-parameter logisticcurve fit.

In this assay, compounds of the invention had an average IC₅₀ below 1000nM. Certain compounds had an average IC₅₀ below 100 nM.

Preparation A

Preparation of (R)-2-(2,5-difluorophenyl)pyrrolidine Step A: Preparationof (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate

A solution of tert-butyl pyrrolidine-1-carboxylate (20 g, 116.8 mmol)and (−) sparteine (32.9, 140 mmol) in MTBE (360 mL) was cooled to −78°C., and sec-BuLi (100 mL, 140 mmol, 1.4 M in cyclohexane) was introduceddrop-wise via cannula, keeping the internal temperature under −70° C.The resulting solution was stirred for 3 hours at −78° C., followed byaddition of a solution of ZnCl₂ (93.4 mL, 93.4 mmol, 1M in Et₂O)drop-wise with rapid stirring, keeping the internal temperature below−65° C. The resulting light suspension was stirred at −78° C. for 30minutes and then warmed to ambient temperature. The resulting mixturewas charged with 2-bromo-1,4-difluorobenzene (14.5 mL, 128 mmol),followed by Pd(OAc)₂ (1.31 g, 5.8 mmol) and t-Bu₃P-HBF₄ (2.03 g, 7.0mmol) in one portion. After stirring overnight at ambient temperature,10.5 mL of NH₄OH solution was added and the reaction was stirred foranother hour. The resulting slurry was filtered through CELITE andwashed with Et₂O (1 L). The filtrate was washed with HCl (0.5 L, 1M aq.)and brine. The organic layer was filtered and concentrated, and thecrude product was purified by silica column chromatography, eluting with5-10% EtOAc/hexanes to give product (R)-tert-butyl2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate as yellow oil (23.9 g,72% yield).

Step B: Preparation of (R)-2-(2,5-difluorophenyl)pyrrolidine

To (R)-tert-butyl 2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate (23.9g, 84.4 mmol) was added 56.2 mL 4N HCl (dioxane). After stirring atambient temperature for 2 hours, 200 mL of ether was added and themixture was stirred for 10 minutes. The resulting slurry was filtered,yielding the hydrochloride salt of the product as a white solid (17.2g). To obtain the free base, the HCl salt product was dispersed in amixture of EtOAc (200 mL) and NaOH solution (100 mL, 2 N aq.) The layerswere separated and the aqueous layer was extracted with EtOAc. Thecombined organic extracts were filtered and concentrated to give thedesired product as a liquid (13.2 g, 85% yield).

The Enantiomeric Excess (Ee %) of (R)-2-(2,5-Difluorophenyl)Pyrrolidinewas Determined as Follows:

To an ethanol solution of (R)-2-(2,5-difluorophenyl)pyrrolidine wasadded excess N-(2,4-dinitro-5-fluorophenyl)-L-alanine amide (FDAA,Marfey's reagent). The mixture was heated to reflux for approximatelytwo minutes. After cooling to ambient temperature, the reaction mixturewas diluted with acetonitrile and injected onto HPLC (YMC ODS-AQ 4.6×50mm 3 μm 120 Å column; mobile phase: 5-95% solvent B in A; solvent A:H₂O/1% IPA/10 mM ammonium acetate, and solvent B: ACN/1% IPA/10 mMammonium acetate; flow rate: 2 mL/min) to determine the enantiomericexcess of the product by calculating the peak areas of the twodiastereomeric derivatives formed. A 1:1 racemic sample was preparedaccording the same procedure described herein, replacing(R)-2-(2,5-difluorophenyl)pyrrolidine with(rac)-2-(2,5-difluorophenyl)pyrrolidine. The ee % of the productobtained as described above was determined to be >93%.

Preparation B

Preparation of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amineStep 1: Preparation of 6-chloro-3-nitroimidazo[1,2-b]pyridazine

6-Chloroimidazo[1,2-b]pyridazine (4.95 g, 31.6 mmol) [purchased fromCombi-Blocks] was dissolved in 60 mL concentrated sulfuric acid, cooledin an ice bath, and nitric acid (9.9 mL, 158 mmol) was added dropwisewhile stirring. The reaction was stirred at 0° C. for 30 minutes, thenat ambient temperature for 4.5 hours to reach completion. The reactionwas poured onto ice, and the resulting aqueous mixture was neutralizedwith 50% NaOH aqueous solution and then extracted with EtOAc (3×400 mL).The organic layers were combined and washed with water (2×400 mL) andbrine (400 mL), dried (Na₂SO₄), filtered and concentrated to yield theproduct as a yellowish powder (5.7 g, 91% yield).

Step 2: Preparation of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-nitroimidazo[1,2-b]pyridazine

A suspension of 6-chloro-3-nitro imidazo[1,2-b]pyridazine (1.0 g, 5.0mmol) and (R)-2-(2,5-difluorophenyl)pyrrolidine (Prepared as describedin Preparation A; 1.9 g, 11 mmol) in n-butanol (4.6 mL, 50 mmol) wassealed in a pressure reaction tube and stirred in a 140° C. oil bathovernight. After cooling to ambient temperature, the reaction mixturewas diluted with EtOAc (250 mL), then washed with water (2×150 mL) andbrine (150 mL), filtered through a Biotage Phase Separator filter paperand concentrated. The crude material was purified by silica gelchromatography, eluting with 2:1 EtOAc/hexanes to yield the product as afoamy yellow powder (1.3 g, 75% yield).

Step 3: Preparation of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine

To a mixture of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-nitroimidazo[1,2-b]pyridazine(4.17 g, 12.1 mmol) and SnCl₂ dihydrate (10.9 g, 48.4 mmol) in a flaskwas added 200 mL EtOH to form a suspension. The reaction was heated at70° C. for 1 hour to reach completion. After cooling to ambienttemperature, the reaction mixture was concentrated. Water (200 mL) wasadded to the resulting crude solid residue, and the mixture was brieflysonicated and then vacuum-filtered. The filtrate pH was neutralized with6N NaOH solution and extracted with DCM (3×250 mL). The combined organiclayers were washed with brine (200 mL), dried over Na₂SO₄, andconcentrated to yield the crude product as a yellowish foamy solid. Thecrude material was purified by C-18 reverse-phase column chromatography(eluent=5 to 60% acetonitrile/water) to provide the pure product as alight yellowish powder (3 g, 78% yield).

Example 1

Preparation of(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-phenylurea

To a DCM (0.1 mL) solution of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine(Preparation B; 6 mg, 0.019 mmol) cooled in an ice bath was added theisocyanatobenzene (2.5 mg, 0.021 mmol) in DCM (0.1 mL) dropwise. Thereaction was slowly warmed to ambient temperature and stirred for 1hour. The reaction was diluted with DCM (2 mL), washed with water, andconcentrated. The crude product was purified by silica gelchromatography (eluent=50% EtOAc/hexanes first, then 5% MeOH in DCM) toyield the pure final product as a solid (5 mg, 60%). MS (apci) m/z=435.2(M+H).

Example 2

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)morpholine-4-carboxamide

To a DCM (1.9 mL) solution of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine(Preparation B; 72 mg, 0.19 mmol) was added 1,1′-carbonyldiimidazole(CDI) (47 mg, 0.29 mmol) at ambient temperature in one portion. Afterstirring for 2 hours, morpholine (34 mg, 0.39 mmol) was added in oneportion. The reaction was stirred for another hour before it wasconcentrated, then directly purified by reverse-phase columnchromatography, eluting with 5 to 60% acetonitrile/water to yield(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)morpholine-4-carboxamideas a solid (64 mg, 77% yield). MS (apci) m/z=429.1 (M+H).

Example 3

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)acetamide

To a DCM (0.1 mL) solution of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine(Preparation B; 6 mg, 0.019 mmol) cooled in an ice bath was added aceticanhydride (2.1 mg, 0.021 mmol), followed by pyridine (2 mg, 0.025 mmol).The reaction was warmed to ambient temperature and stirred for 1 hourbefore it was concentrated and directly purified by reverse-phase columnchromatography, eluting with 5 to 60% acetonitrile/water to yield(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)acetamideas an off-white solid (6 mg, 81% yield). MS (apci) m/z=358.2 (M+H).

Example 4

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-(methylsulfonamido)benzamide

A reaction vial was charged with(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine(Preparation B; 30 mg, 0.095 mmol), 4-(methylsulfonamido)benzoic acid(41 mg, 0.19 mmol), and 2(1H-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluranium hexafluorophosphate methanaminium (HATU; 72 mg, 0.19 mmol). DMF(0.8 mL) was added to the mixture to make a solution. The reactionmixture was cooled in an ice bath for 10 minutes before DIEA (0.05 mL,0.29 mmol) was added dropwise. After addition, reaction was warmed toambient temperature and stirred overnight. The reaction mixture wasdiluted with EtOAc (20 mL), washed with water and brine (10 mL each),and concentrated. The crude material was purified by reverse-phasecolumn chromatography, eluting with 5 to 60% acetonitrile/water to yield(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-(methylsulfonamido)benzamideas a yellowish solid (13 mg, 27% yield). MS (apci negative) m/z=511.4(M−H).

Example 5

(R)-1-(3-cyanophenyl)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea

To a DCM (0.1 mL) solution of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine(Preparation B; 6 mg, 0.019 mmol) cooled in an ice bath was added3-cyanophenylisocyanate (14 mg, 0.095 mmol) in DCM (0.1 mL) drop-wise.The reaction was slowly warmed to ambient temperature and stirred for 1hour. The reaction was diluted with DCM (2 mL), washed with water, andconcentrated. The crude material was purified by reverse-phase columnchromatography, eluting with 5 to 85% acetonitrile/water to yield thepure final product as a solid (3.2 mg, 37% yield). MS (apci) m/z=460.2(M+H).

Example 6

(R)-1-(4-cyanophenyl)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea

Prepared according to Example 5, replacing 3-cyanophenylisocyanate with4-cyanophenylisocyanate to yield the final product as a solid. MS (apci)m/z=460.2 (M+H).

Example 7

(R)-1-(2,4-dichlorophenyl)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea

Prepared according to Example 5, replacing 3-cyanophenylisocyanate with2,4-dichlorophenylisocyanate to yield the final product as a solid. MS(apci) m/z=503.1, 505.1 (M+H, M+3H).

Example 8

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(3-(trifluoromethyl)phenyl)urea

Prepared according to Example 5, replacing 3-cyanophenylisocyanate with3-trifluoromethylphenylisocyanate to yield the final product as a solid(6.5 mg, 68% yield). MS (apci) m/z=503.2 (M+H).

Example 9

(R)-1-(3,5-dichlorophenyl)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea

Prepared according to Example 5, replacing 3-cyanophenylisocyanate with3,5-dichlorophenylisocyanate to yield the final product as a solid. MS(apci) m/z=503.1 (M+H), 505.1 (M+3H).

Example 10

(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Prepared according to the method of Example 2, replacing morpholine with(S)-pyrrolidin-3-ol[purchased from SUVEN Life Sciences] to yield thefinal product as a solid (79 mg, 68% yield). MS (apci) m/z=429.2 (M+H).

Example 11

(R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Prepared according to the method of Example 2, replacing morpholine with(R)-pyrrolidin-3-ol to yield the final product as a solid (8 mg, 77%yield). MS (apci) m/z=429.2 (M+H).

Example 11A

(R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamidehydrochloride

To a methanol (1 mL) solution of(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide(10.1 mg, 0.0236 mmol) was added HCl as a solution is dioxane (30 μL).After minutes, the reaction was concentrated to provide(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamidehydrochloride as a yellow solid.

Example 12

(R)-tert-butyl1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidin-4-ylcarbamate

Prepared according to the method of Example 2, replacing morpholine withtert-butyl piperidin-4-ylcarbamate to yield the final product as a solid(10 mg, 76% yield). MS (apci) m/z=542.2 (M+H).

Example 13

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxyazetidine-1-carboxamide

To a DCM (1 mL) solution of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine(Preparation B; 50 mg, 0.16 mmol) was added CDI (39 mg, 0.24 mmol) atambient temperature in one portion while stirring. After 1 hourstirring, azetidin-3-ol hydrochloride (35 mg, 0.32 mmol) [purchased fromOakwood] was added in one portion, followed by addition of DIEA (83 μL,0.48 mmol). The reaction mixture was briefly sonicated to help break upthe solid particles from azetidine material. After 30 minute stirring atambient temperature, the reaction was concentrated and directly purifiedby reverse-phase column chromatography, eluting with 5 to 50%acetonitrile/water to yield the final product as a pale-yellowish solid(65 mg, 99% yield). MS (apci) m/z=415.2 (M+H).

Example 14

(R)-tert-butyl1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)azetidin-3-ylcarbamate

Prepared according to the method of Example 2, replacing morpholine withtert-butyl azetidin-3-ylcarbamate to yield the final product as a solid(10 mg, 80% yield). MS (apci) m/z=514.2 (M+H).

Example 15

(R)-tert-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperazine-1-carboxylate

Prepared according to the method of Example 2, replacing morpholine withtert-butyl piperazine-1-carboxylate to yield the final product as asolid (10 mg, 78% yield). MS (apci) m/z=528.2 (M+H).

Example 16

(R)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1,1-dimethylurea

Prepared according to the method of Example 2, replacing morpholine withdimethylamine to yield the final product as a solid (8 mg, 85% yield).MS (apci) m/z=387.2 (M+H).

Example 17

tert-Butyl1-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidin-3-ylcarbamate

Prepared according to the method of Example 2, replacing morpholine withtert-butyl piperidin-3-ylcarbamate to yield the final product as a solid(10 mg, 76% yield). MS (apci) m/z=542.3 (M+H).

Example 18

(R)-4-amino-N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide

(Example 12, 10 mg, 0.018 mmol) was dissolved in 0.2 mL DCM, followed byaddition of 0.5 mL 4 N HCl (dioxane) solution in one portion. Afterstirring at ambient temperature overnight, the reaction was concentratedto yield the final product salt form as a light yellowish solid. MS(apci) m/z=442.1 (M+H).

Example 19

(R)-3-amino-N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)azetidine-1-carboxamidetrifluoroacetate

(R)-tert-butyl1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)azetidin-3-ylcarbamate(Example 14; 10 mg, 0.019 mmol) was dissolved in 0.5 mL 50% TFA in DCMand stirred at ambient temperature for 2 hours. The reaction isconcentrated, treated with ether, and concentrated again to yield thefinal product salt form as a white solid. MS (apci) m/z=414.2 (M+H).

Example 20

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperazine-1-carboxamidehydrochloride

(R)-tert-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperazine-1-carboxylate(Example 15; 10 mg, 0.019 mmol) was dissolved in 0.2 mL DCM, followed byaddition of 0.5 mL 4 N HCl (dioxane) solution in one portion. Afterstirring at ambient temperature overnight, the reaction was concentratedto yield the final product salt form as a light yellowish solid. MS(apci) m/z=428.2 (M+H).

Example 21

3-Amino-N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamidehydrochloride

tert-Butyl1-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidin-3-ylcarbamate(Example 17; 10 mg, 0.018 mmol) was dissolved in 0.1 mL DCM, followed byaddition of 0.5 mL 4 N HCl (dioxane) solution in one portion. Afterstirring at ambient temperature overnight, the reaction was concentratedto yield the final product salt form as a light yellowish solid. MS(apci) m/z=442.1 (M+H).

Example 22

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(4-fluorophenyl)urea

Prepared according to Example 5, replacing 3-cyanophenylisocyanate with1-fluoro-4-isocyanatobenzene to yield the final product as a solid. MS(apci) m/z=453.2 (M+H).

Example 23

tert-Butyl3-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

Prepared according to the method of Example 2, replacing morpholine withtert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate to yield thefinal product as a solid. MS (apci) m/z=554.2 (M+H).

Example 24

N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxamidehydrochloride

tert-Butyl3-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate(Example 23, 10 mg, 0.018 mmol) was dissolved in 0.1 mL DCM, followed byaddition of 0.5 mL 4 N HCl (dioxane) solution in one portion. Afterstirring at ambient temperature overnight, the reaction was concentratedto yield the final product salt form as a light yellowish solid. MS(apci) m/z=454.1 (M+H).

Example 25

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-hydroxypiperidine-1-carboxamide

Prepared according to the method of Example 2, replacing morpholine withpiperidin-4-ol to yield the final product as a solid. MS (apci)m/z=443.2 (M+H).

Example 26

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide

Prepared according to the method of Example 2, replacing morpholine withpiperidine, to yield the final product as a solid. MS (apci) m/z=427.2(M+H).

Example 26A

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamidehydrochloride

To a methanol (1 mL) solution of(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide(4.9 mg, 0.011 mmol) was added HCl as a solution is dioxane (30 μL).After 30 minutes, the reaction was concentrated to provide(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamidehydrochloride (4.2 mg, 0.0091 mmol, 79% yield) as a yellow solid. MS(apci) m/z=427.4 (M+H).

Example 27

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea

Prepared according to the method of Example 2, replacing morpholine withammonia, to yield the final product as a solid. MS (apci) m/z=359.2(M+H).

Example 28

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-methylurea

Prepared according to the method of Example 2, replacing morpholine withmethylamine, to yield the final product as a solid. MS (apci) m/z=373.2(M+H).

Example 29

(R)-1-tert-butyl-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)urea

Prepared according to Example 5, replacing 3-cyanophenylisocyanate with2-isocyanato-2-methylpropane, to yield the final product as a solid. MS(apci) m/z=415.2 (M+H).

Example 30

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(4-methoxyphenyl)urea

Prepared according to Example 5, replacing 3-cyanophenylisocyanate with1-isocyanato-4-methoxybenzene to yield the final product as a solid (7.5mg, 85% yield). MS (apci) m/z=465.2 (M+H).

Example 31

(R)-ethyl1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidine-4-carboxylate

Prepared according to the method of Example 2, replacing morpholine withethyl piperidine-4-carboxylate, to yield the final product as a solid.MS (apci) m/z=499.2 (M+H).

Example 32

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(3,4,5-trimethoxyphenyl)urea

Prepared according to Example 5, replacing 3-cyanophenylisocyanate with5-isocyanato-1,2,3-trimethoxybenzene to yield the final product as asolid (3.2 mg, 32% yield). MS (apci) m/z=525.2 (M+H).

Example 33

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(3,5-dimethylisoxazol-4-yl)urea

Prepared according to Example 5, replacing 3-cyanophenylisocyanate with4-isocyanato-3,5-dimethylisoxazole to yield the final product as a solid(8.1 mg, 94% yield). MS (apci) m/z=454.2 (M+H).

Example 34

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidine-4-carboxylicacid

(R)-ethyl1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidine-4-carboxylate(Example 31, 9.2 mg, 0.018 mmol) was dissolved in a mixture solvent ofTHF:MeOH:water (2:2:1 v/v; 0.2 mL), followed by addition of lithiumhydroxide monohydrate (2.3 mg, 0.055 mmol). After stirring at ambienttemperature overnight, the reaction was diluted with water (1 mL),acidified with 10% citric acid, and extracted with EtOAc (3×1 mL). Thecombined organic layers were concentrated, and the crude material waspurified by reverse-phase column chromatography, eluting with 5 to 55%MeOH/water to yield the final product as a solid. MS (apci) m/z=471.2(M+H).

Example 35

N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,5-dimethylpiperazine-1-carboxamide

Prepared according to the method of Example 2, replacing morpholine with2,6-dimethylpiperazine to yield the final product as a yellowish foamypowder (7.5 mg, 61% yield). MS (apci) m/z=456.2 (M+H).

Example 36

(R)-tert-butyl4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-methylpiperazine-1-carboxylate

Prepared according to the method of Example 2, replacing morpholine with(R)-tert-butyl 2-methylpiperazine-1-carboxylate, to yield the finalproduct as an off-white foamy powder (12 mg, 82% yield). MS (apci)m/z=542.2 (M+H).

Example 37

(S)-tert-butyl4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-methylpiperazine-1-carboxylate

Prepared according to the method of Example 2, replacing morpholine with(S)-tert-butyl 2-methylpiperazine-1-carboxylate to yield the desiredproduct as an off-white foamy powder (10 mg, 69% yield). MS (apci)m/z=542.2 (M+H).

Example 38

(R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-methylpiperazine-1-carboxamidehydrochloride

To a reaction vial containing (R)-tert-butyl4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-methylpiperazine-1-carboxylate(Example 36; 12 mg, 0.022 mmol) was added 0.5 mL 4 N HCl (dioxane)solution in one portion. After stirring at ambient temperature for 4hours, the reaction was concentrated. The resulting solid residue wastreated with ether and concentrated again to yield the final productsalt form as a pale-yellowish powder. MS (apci) m/z=442.2 (M+H).

Example 39

(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-methylpiperazine-1-carboxamide

Prepared according to the method of Example 38, replacing (R)-tert-butyl4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-methylpiperazine-1-carboxylatewith (S)-tert-butyl 4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-methylpiperazine-1-carboxylate(Example 37). The final product was a fine pale-yellowish powder. MS(apci) m/z=442.2 (M+H).

Example 40

(3R,4R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,4-dihydroxypyrrolidine-1-carboxamide

Prepared according to the method of Example 2, replacing morpholine with(3R,4R)-pyrrolidine-3,4-diol[obtained from benzyl de-protection ofcommercially available (3R,4R)-1-benzylpyrrolidine-3,4-diol] to yieldthe final product as a solid (11 mg, 92% yield). MS (apci) m/z=445.2(M+H).

Example 41

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)piperidin-4-sulfone

Prepared according to the method of Example 2, replacing morpholine withpiperidin-4-sulfone to yield the final product as a solid (10 mg, 78%yield). MS (apci) m/z=477.2 (M+H).

Example 42

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-oxopiperazine-1-carboxamide

Prepared according to the method of Example 2, replacing morpholine withpiperazin-2-one to yield the final product as a solid (10 mg, 84%yield). MS (apci) m/z=442.1 (M+H).

Example 43

N-(6-(2-(3-fluorophenyl)piperidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxyazetidine-1-carboxamideStep 1: Preparation of6-(2-(3-fluorophenyl)piperidin-1-yl)-3-nitroimidazo[1,2-b]pyridazine

To a pressure reaction tube were charged6-chloro-3-nitroimidazo[1,2-b]pyridazine (450 mg, 2.27 mmol),2-(3-fluorophenyl)piperidine (609 mg, 3.40 mmol, purchased fromChemBridge), and N-ethyl-N-isopropylpropan-2-amine (0.51 mL, 2.95 mmol),followed by addition of 1.0 mL n-butanol. The reaction mixture was thensealed and stirred at 180° C. for 24 hours. After completion, thereaction was cooled to ambient temperature, and diluted with water andEtOAc. The organic layer was separated, and the aqueous layer wasextracted with EtOAc twice. The combined organic layers was dried overNa₂SO₄ and concentrated. The crude product was purified by silica columnchromatography, eluting with 20 to 50% EtOAc in hexanes to yield thedesired product for the next step.

Step 2: Preparation of6-(2-(3-fluorophenyl)piperidin-1-yl)imidazo[1,2-b]pyridazin-3-amine

A mixture of6-(2-(3-fluorophenyl)piperidin-1-yl)-3-nitroimidazo[1,2-b]pyridazine (50mg, 0.146 mmol) and SnCl₂ dihydrate (165 mg, 0.732 mmol) in 5 mL EtOHwas first stirred at 70° C. for 30 minutes, then cooled to ambienttemperature and concentrated. EtOAc and water (10 mL each) were added tothe solid residue, followed by Na₂CO₃ aqueous solution (2 mL×2 N) toobtain a phase break. The organic layer was separated, and the aqueouslayer was extracted with EtOAc (3×10 mL). The combined organic layerswas dried with Na₂SO₄ and concentrated to provide the product for thenext step.

Step 3: Preparation ofN-(6-(2-(3-fluorophenyl)piperidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxyazetidine-1-carboxamide

To a DCM (2 mL) solution of6-(2-(3-fluorophenyl)piperidin-1-yl)imidazo[1,2-b]pyridazin-3-amine (45mg, 0.14 mmol) was added CDI (35 mg, 0.22 mmol) at ambient temperaturein one portion. After stirring for five hours, azetidin-3-olhydrochloride (54 mg, 0.33 mmol) was added in one portion, followed byDIEA (0.05 mL, 0.29 mmol), and the reaction was stirred at ambienttemperature overnight. The reaction was diluted with DCM, washed withwater, dried over Na₂SO₄ and concentrated. The crude product waspurified by reversed phase column, eluting with 0 to 55% CH₃CN/water toobtain the desired product as a solid (30 mg, 51% yield). MS (apci)m/z=411.2 (M+H).

Example 44

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-difluoropyrrolidine-1-carboxamide

Prepared according to Example 13, replacing azetidin-3-ol hydrochloridewith 3,3-difluoropyrrolidine hydrochloride to yield the final product asa white solid. MS (apci) m/z=449.2 (M+H).

Example 45

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-difluoroazetidine-1-carboxamide

Prepared according to Example 13, replacing azetidin-3-ol hydrochloridewith 3,3-difluoroazetidine hydrochloride to yield the final product as asolid (20 mg, 77% yield). MS (apci) m/z=435.2 (M+H).

Example 46

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)azetidine-1-carboxamide

Prepared according to Example 13, replacing azetidin-3-ol hydrochloridewith azetidine to yield the final product as a solid (20 mg, 77% yield).MS (apci) m/z=399.2 (M+H).

Example 47

(R)-3-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-(2-hydroxyethyl)-1-methylurea

Prepared according to Example 13, replacing azetidin-3-ol hydrochloridewith 2-(methylamino)ethanol to yield the final product as a solid (20mg, 81% yield). MS (apci) m/z=417.2 (M+H).

Example 48

(R)-tert-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2,2-dimethylpiperazine-1-carboxylate

Prepared according to the method of Example 2, replacing morpholine withtert-butyl 2,2-dimethylpiperazine-1-carboxylate to yield the finalproduct as a solid (40 mg, 91% yield). MS (apci) m/z=556.3 (M+H).

Example 49

(S)-tert-butyl4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-isopropylpiperazine-1-carboxylate

Prepared according to the method of Example 2, replacing morpholine with(S)-tert-butyl 2-isopropylpiperazine-1-carboxylate to yield the finalproduct as a white foamy solid (42 mg, 93% yield). MS (apci) m/z=570.3(M+H).

Example 50

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-dimethylpiperazine-1-carboxamidetrifluoroacetate

To a reaction vial containing (R)-tort-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2,2-dimethylpiperazine-1-carboxylate(Example 48, 33.5 mg, 0.06 mmol) was added 1 mL TFA/DCM (1:1 v/v) andleft at ambient temperature for 1 hour. After removal of solvent, thecrude oil was treated with ether and gave the product TFA salt as awhite solid. MS (apci) m/z=456.2 (M+H).

Example 51

(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-isopropylpiperazine-1-carboxamide

Prepared according to the method of Example 50, replacing (R)-tert-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2,2-dimethylpiperazine-1-carboxylatewith (S)-tert-butyl4-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2-isopropylpiperazine-1-carboxylate(Example 49). The final product was a fine white solid. MS (apci)m/z=470.2 (M+H).

Example 52

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamide

Prepared according to Example 13, replacing azetidin-3-ol hydrochloridewith azetidin-3-ylmethanol hydrochloride to yield the final product as apale-yellowish solid (18 mg, 53% yield). MS (apci) m/z=429.2 (M+H).

Example 52A

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamidehydrochloride

To a methanol (1 mL) solution of(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamide(9.9 mg, 0.0231 mmol) was added HCl as a solution is dioxane (30 μL).After 30 minutes, the reaction was concentrated to provide(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamidehydrochloride (10.2 mg, 0.0219 mmol, 94.9% yield) as a yellow solid. MS(apci) m/z=429.4 (M+H).

Example 53

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-methoxyazetidine-1-carboxamide

Prepared according to Example 13, replacing azetidin-3-ol hydrochloridewith 3-methoxyazetidine hydrochloride to yield the final product as apale-yellowish solid (60 mg, 88% yield). MS (apci) m/z=429.2 (M+H).

Example 54

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxy-3-methylazetidine-1-carboxamide

Prepared according to Example 13, replacing azetidin-3-ol hydrochloridewith 3-methylazetidin-3-ol hydrochloride to yield the final product as apale-yellowish solid (63 mg, 93% yield). MS (apci) m/z=429.2 (M+H).

Example 54A

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxy-3-methylazetidine-1-carboxamidehydrochloride

To a methanol (1 mL) solution of(R)—N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxy-3-methylazetidine-1-carboxamide(10.2 mg, 0.0238 mmol) was added HCl as a solution is dioxane (30 μL).After 30 minutes, the reaction was concentrated to provide(R)—N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxy-3-methylazetidine-1-carboxamidehydrochloride (8.3 mg, 0.0179 mmol, 75.0% yield) as a yellow solid.

Example 55

(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)azetidin-3-ylisobutyrate

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxyazetidine-1-carboxamide(Example 13; 21.5 mg, 0.05 mmol) was first dissolved in 0.5 mL DMF,followed by addition of isobutyric anhydride (24 mg, 0.15 mmol) and afew drops of DIEA. After overnight stirring at ambient temperature, thecrude material was concentrated and directly purified by silicachromatography, eluting with 3 to 8% MeOH in DCM to provide the finalproduct as a beige foamy solid (12 mg, 50% yield). MS (apci) m/z=485.2(M+H).

Example 56

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

Prepared according to Example 4, replacing 4-(methylsulfonamido)benzoicacid with 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid to yieldthe final product as a yellowish solid (16 mg, 37% yield). MS (apci)m/z=451.2 (M+H).

Example 57

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

Prepared according to Example 4, replacing 4-(methylsulfonamido)benzoicacid with 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid. Theresulting light yellowish heavy suspension was vacuum-filtered, and thesolid was rinsed with acetonitrile and ether, giving the first batch ofpure product as a yellow powder (52 mg). A second batch of product wasobtained through treating the concentrated filtrate from above withreverse-phase chromatography, eluting with 5 to 60% acetonitrile/water(total product from combining two batches: 65 mg, 91% yield). MS (apci)m/z=452.3 (M+H).

Example 58

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-methylpiperazine-1-carboxamide

Prepared according to the method of Example 2, replacing morpholine with1-methylpiperazine, to yield the final product as a pale-yellowish foamysolid (4.5 mg, 63% yield). MS (apci) m/z=442.1 (M+H).

Example 59

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-hydroxy-4-(trifluoromethyl)piperidine-1-carboxamide

Prepared according to Example 13, replacing azetidin-3-ol hydrochloridewith 4-(trifluoromethyl)piperidin-4-ol, to yield the final product as apale-yellowish solid (35 mg, 86% yield). MS (apci) m/z=511.2 (M+H).

Example 60

(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-2,2,2-trifluoroacetamide

A DCM (1 mL) solution of(R)-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine(Preparation B; 50 mg, 0.16 mmol) was cooled in an ice bath, followed byaddition of 2,2,2-trifluoroacetic anhydride (24 μl, 0.17 mmol) andpyridine (14 μl, 0.17 mmol) drop-wise. The ice bath was removed afterreagent addition and the reaction was warmed to ambient temperature.After stirring for one hour, the reaction was concentrated and directlypurified by reverse-phase column chromatography, eluting with 5 to 70%acetonitrile/water to yield the final product as an off-white powder (45mg, 69% yield). MS (apci) m/z=412.3 (M+H).

1. (canceled)
 2. A method for attenuating or ameliorating one or moresymptoms of a solid tumor in a mammal in need thereof, the methodcomprising: (a) determining if the tumor exhibits one or more ofoverexpression, activation, amplification, and mutation of a Trk kinase;and (b) if the tumor is determined to exhibit one or more ofoverexpression, activation, amplification, and mutation of a Trk kinase,administering to the mammal a therapeutically effective amount of acompound selected from the group consisting of:(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)acetamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-(methylsulfonamido)benzamide;(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;(R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-hydroxypiperidine-1-carboxamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide;(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(4-methoxyphenyl)urea;(3R,4R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,4-dihydroxypyrrolidine-1-carboxamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-difluoropyrrolidine-1-carboxamide;(R)-tert-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2,2-dimethylpiperazine-1-carboxylate;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamide;and(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide;or a pharmaceutically acceptable salt thereof.
 3. The method of claim 2,wherein the solid tumor is selected from the group consisting of:breast, prostate, lung, renal, thyroid, neuroblastoma, ovarian cancer,breast cancer, pancreatic cancer, astrocytoma amd medulloblastoma,glioma, melanoma, lung adenocarcinoma, large cell neuroendocrine tumors,colorectal cancer, stomach, bladder, uterus, rectum, and kidney.
 4. Themethod of claim 2, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)acetamide,or a pharmaceutically acceptable salt thereof.
 5. The method of claim 2,wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-(methylsulfonamido)benzamide,or a pharmaceutically acceptable salt thereof.
 6. The method of claim 2,wherein the compound is(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 7. The method of claim 2,wherein the compound is(R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 8. The method of claim 2,wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-hydroxypiperidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 9. The method of claim 2,wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 10. The method of claim2, wherein the compound is(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(4-methoxyphenyl)urea,or a pharmaceutically acceptable salt thereof.
 11. The method of claim2, wherein the compound is(3R,4R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,4-dihydroxypyrrolidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 12. The method of claim2, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-difluoropyrrolidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 13. The method of claim2, wherein the compound is (R)-tert-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2,2-dimethylpiperazine-1-carboxylate,or a pharmaceutically acceptable salt thereof.
 14. The method of claim2, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 15. The method of claim2, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide,or a pharmaceutically acceptable salt thereof.
 16. The method of claim2, wherein the compound is selected from the group consisting of:(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)acetamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-(methylsulfonamido)benzamide;(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;(R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-hydroxypiperidine-1-carboxamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide;(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(4-methoxyphenyl)urea;(3R,4R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,4-dihydroxypyrrolidine-1-carboxamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-difluoropyrrolidine-1-carboxamide;(R)-tert-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2,2-dimethylpiperazine-1-carboxylate;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamide;and(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide.17. The method of claim 2, wherein the compound is in the form of apharmaceutically acceptable salt.
 18. A method for attenuating orameliorating one or more symptoms of a solid tumor exhibiting one ormore of overexpression, activation, amplification, and mutation of a Trkkinase in a mammal in need thereof, the method comprising administeringto the mammal a therapeutically effective amount of a compound selectedfrom the group consisting of:(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)acetamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-(methylsulfonamido)benzamide;(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;(R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-hydroxypiperidine-1-carboxamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide;(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(4-methoxyphenyl)urea;(3R,4R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,4-dihydroxypyrrolidine-1-carboxamide;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-difluoropyrrolidine-1-carboxamide;(R)-tert-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2,2-dimethylpiperazine-1-carboxylate;(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamide;and(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide;or a pharmaceutically acceptable salt thereof; and a pharmaceuticallyacceptable diluent or carrier.
 19. The method of claim 18, wherein thesolid tumor is selected from the group consisting of: breast, prostate,lung, renal, thyroid, neuroblastoma, ovarian cancer, breast cancer,pancreatic cancer, astrocytoma amd medulloblastoma, glioma, melanoma,lung adenocarcinoma, large cell neuroendocrine tumors, colorectalcancer, stomach, bladder, uterus, rectum, and kidney.
 20. The method ofclaim 18, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)acetamide,or a pharmaceutically acceptable salt thereof.
 21. The method of claim18, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-(methylsulfonamido)benzamide,or a pharmaceutically acceptable salt thereof.
 22. The method of claim18, wherein the compound is(S)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 23. The method of claim18, wherein the compound is(R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-hydroxypyrrolidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 24. The method of claim18, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-4-hydroxypiperidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 25. The method of claim18, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)piperidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 26. The method of claim18, wherein the compound is(R)-1-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(4-methoxyphenyl)urea,or a pharmaceutically acceptable salt thereof.
 27. The method of claim18, wherein the compound is(3R,4R)—N-(6-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,4-dihydroxypyrrolidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 28. The method of claim18, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3,3-difluoropyrrolidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 29. The method of claim18, wherein the compound is (R)-tert-butyl4-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2,2-dimethylpiperazine-1-carboxylate,or a pharmaceutically acceptable salt thereof.
 30. The method of claim18, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-3-(hydroxymethyl)azetidine-1-carboxamide,or a pharmaceutically acceptable salt thereof.
 31. The method of claim18, wherein the compound is(R)—N-(6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide,or a pharmaceutically acceptable salt thereof.